Navigation Links
Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma
Date:6/2/2008

iscovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases and cancer, as well as viral and metabolic diseases. Our goal is to file one new investigational new drug (IND) application in a significant indication each year. Rigel has achieved this goal every year since 2002. Our pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. Rigel's productivity has resulted in strategic collaborations with large pharmaceutical partners to develop and market our product candidates. Rigel has product development programs in inflammatory/autoimmune diseases such as rheumatoid arthritis, thrombocytopenia and asthma, as well as in cancer.

Contact: Raul Rodriguez

Phone: 650.624.1302

Email: invrel@rigel.com

Media Contact: Susan C. Rogers, Alchemy Consulting, Inc.

Phone: 650.430.3777

Email: susan@alchemyemail.com


'/>"/>
SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Rigels R788 Slows Progression of Murine Lupus in Preclinical Studies
2. Rigels R788 Shows Preclinical Activity in Type 1 Diabetes Model
3. Rigel Announces Initiation of Phase 1 Clinical Trial of R348 for Rheumatoid Arthritis, Psoriasis and Other Immune Disorders
4. Rigels R788 Demonstrates Significant Improvement in Rheumatoid Arthritis in Phase 2 Clinical Study
5. Rigel Announces Initiation of Phase 1 Clinical Trial of R343 for Allergic Asthma by its Partner Pfizer
6. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
7. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
8. Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference
9. PRoFESS(R) Results Announced at XVII European Stroke Conference
10. Neurobiological Technologies, Inc. Presents Dosing Rationale for Viprinex(TM) (ancrod) at the European Stroke Conference
11. Annual Conference on Vaccine Research to Highlight Not Only Health Benefits But Also Economic Gains
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2008)...der with Strong Clinical Research Relationships an...ations to Lead Commercialization, SANTA CLARA, Ca... Inc.,(OTC Bulletin Board: NWCI) a cardiac diagno...ncent W. Renz has joined NewCardio as its presiden...zation effort, to include,business development, cl...
(Date:8/17/2008)...tralia, Aug. 17 /Xinhua-- P...that the first pivotal Phase 3,clinical trial of B...,completed enrolment., The first efficacy data fr...e first half of 2009. The trial commenced its dosi...tment target of 250 subjects in June,2008 and clos...
(Date:8/14/2008)...A Complimentary Continuing Education Activity, VO...rus (CMV) is a,significant cause of morbidity and ... transplantation. The clinical manifestations of C...inal disease to life-threatening,pneumonia, myelos...r to prevent CMV infection and reduce CMV drug res...
(Date:8/14/2008)...EACH, Fla., Aug. 14 /- The Clinical T...ed at educating physicians,clinical coordinators,...,clinical trial. It will be held in Boca Raton at ...investigators, clinical coordinators, monitors and... about how to incorporate,clinical trials into a p...
Breaking Medicine Technology:Vincent W. Renz Joins NewCardio as President 2Vincent W. Renz Joins NewCardio as President 3Vincent W. Renz Joins NewCardio as President 4Bronchitol Phase 3 Cystic Fibrosis Trial Completes Recruitment 2CMV Disease in Stem Cell Transplantation: Prevention and Drug Resistance 2Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings Inc Prompt Notice of Noncompliance from the Nasdaq Global Market 14205 1Previously Disclosed Changes in Board Composition of NightHawk Radiology Holdings Inc Prompt Notice of Noncompliance from the Nasdaq Global Market 14205 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 1WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 2WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 3WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 4WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 5WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 6WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 7WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 8WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 9WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 10WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 11WuXi PharmaTech Announces Fourth Quarter and Full Year 2007 Results 3916 12Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 14201 1Cardiac Science to Present at the Seventh Annual Invest Northwest Conference 14201 2deCODE Genetics Announces Full year 2007 Financial Results 3913 1deCODE Genetics Announces Full year 2007 Financial Results 3913 2deCODE Genetics Announces Full year 2007 Financial Results 3913 3deCODE Genetics Announces Full year 2007 Financial Results 3913 4deCODE Genetics Announces Full year 2007 Financial Results 3913 5deCODE Genetics Announces Full year 2007 Financial Results 3913 6deCODE Genetics Announces Full year 2007 Financial Results 3913 7deCODE Genetics Announces Full year 2007 Financial Results 3913 8deCODE Genetics Announces Full year 2007 Financial Results 3913 9
...rCare offers five questions to help women,learn ab...June 12, 2007 – According to a new,GfK Roper...national,nonprofit cancer support organization, wh...id they know at least a fair amount,about breast c...,progress made in treatment. Fewer than one out of...
..., June 13, 2007--Three new drugs for,rheumatoid ar...t,for this difficult and debilitating condition. T... published early Online and in an,upcoming edition...onic,inflammatory joint diseases, affecting 0&midd...sed world. Its typical symptoms are,joint pain, st...
Other Medicine Technology:Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 2Women Well-Informed About Breast Cancer, Yet Lacking Knowledge,About Current Treatments, New Survey Finds 3Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 2Three New Drugs Mark New Era in Rheumatoid Arthritis Treatment 3
(Date:8/21/2008)... New names and fresh websit... UME/GME administration software , ... one45 Software, a leading provider of healthcare ... of Cytiva Software Inc. (CRX:TSX.V), announced to...hcare education administration products., , ,Compl...
(Date:8/20/2008)... NEWTON, Mass., Aug. 20 /PRNewswire/ -- Questex M...o-business media company and owner of,American Spa... and the,International Beauty Shows, the Internati...) and the SPATEC appointment events today announce...stry portals SpaTrade (, http://www.SpaTrade.com ...
(Date:8/20/2008)... Survey Report Is Available at http://ww...Newswire/ -- A new survey released today,documents...re leveraging,health information technology (HIT) ...The survey results highlight the need for many HIT...dization and,interoperability to optimize clinical...
(Date:8/20/2008)...use postponed reproductive onset in teen, adult fe...EDNESDAY, Aug. 20 (HealthDay News) -- Alcoholism i...ccording to a study that compared women,s and men,... age when they had their first child. , The re...ian twins born between 1893-1964 (3,634 female and...
Breaking Medicine News(10 mins):Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 2Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 3Health News:Cytiva's one45 Software Rebrands Healthcare Education Administration Products 4Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 2Health News:Questex Acquires Leading Spa Industry Portal and Spa Executive Business Networking Site and Events 3Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 2Health News:New Health IT Survey for Care Management Services Shows Opportunities for Integration, Standardization and Innovation 3Health News:Women's Alcohol Use Tied to Delayed Childbearing 2
...oped by scientists to enable the easy detection of...are two factors which are called for// where cance...archers led by Professor Calum McNeil are engaged ...er markers - proteins or other molecules produced ...
... statement, highlighting the unwillingness of Chin... bird flu outbreaks.// This was stated following a...ath, by Beijing. The deadly avian bird flu virus ...41-year-old factory worker, from the Southeastern ...
...ence of H5N1 bird flu strain in the poultry sample... the deadly bird flu strain // in six villages Mod... of Romania. Early this month five new cases of ... in Buzau County. Bird flu was first detected in D...
... at the UT Southwestern Medical Center has found t... urinary bladder if a woman is coached during labo... presence of a coach does not seem to provide any ...shortening labor. The study is the first of its k...
Other Medicine News:Health News:Coaching In Labor Could Increase Bladder Problems 2
...e (GH) is a monomeric protein produced and stored ...H is released from the pituitary into the bloodstr...trol of hypothalamic somatostatin (SS) and GH-rele...of GH release appears to be regulated by somatosta...
...he most potent glucocorticoid produced by the huma...d with high affinity to corticosteroid-binding glo...lbumin. Cortisol acts on specific intracellular re...ms, including immune function, glucose counter-reg...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
...growth factor I (IGF-I or somatomedin C) is a 7.6 ...ts as a potent mitogen of cellular proliferation, ...urface receptors. In the circulation, IGF-I is bou...to regulate the actions of IGF-I by modulating the...
Medicine Products: